News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Avigen, Inc.'s Spasticity Drug Fails in Trial, Shares Tank
October 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Oct 21 (Reuters) - Biopharmaceutical company Avigen Inc said its experimental treatment for spasticity associated with multiple sclerosis (MS), AV650, failed to meet the main goal of a mid-stage trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
MORE ON THIS TOPIC
Lung cancer
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd
September 8, 2025
·
2 min read
·
Tristan Manalac
Psychedelics
With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’
September 5, 2025
·
3 min read
·
Dan Samorodnitsky
Immunology and inflammation
Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study
September 5, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
·
4 min read
·
Annalee Armstrong
